Clinical Trials in Shenzhen, China
5 recruiting
Showing 1–20 of 33 trials
Recruiting
Phase 2Phase 3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Advanced Non-Small Cell Lung Cancer
Mirati Therapeutics Inc.806 enrolled764 locationsNCT04613596
Recruiting
Phase 2Phase 3
A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Bristol-Myers Squibb590 enrolled262 locationsNCT07063745
Recruiting
Phase 1Phase 2
Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
Beijing Biotech60 enrolled1 locationNCT07480213
Recruiting
Phase 3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Mirati Therapeutics Inc.630 enrolled337 locationsNCT06875310
Recruiting
Phase 1Phase 2
Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC
Beijing Biotech48 enrolled1 locationNCT07467863
Recruiting
Phase 3
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Eli Lilly and Company700 enrolled353 locationsNCT06890598
Recruiting
Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
AstraZeneca880 enrolled300 locationsNCT06692738
Recruiting
Phase 1Phase 2
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Advanced or Metastatic Non-small Cell Lung Cancer
AstraZeneca152 enrolled105 locationsNCT06996782
Recruiting
Phase 3
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
Gilead Sciences695 enrolled204 locationsNCT06801834
Recruiting
Phase 2
A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positvie ctDNA After lead-in Osimertinib Monotherapy
Guangdong Association of Clinical Trials120 enrolled4 locationsNCT07375316
Recruiting
A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
EGFR Mutant Advanced Non-small Cell Lung CancerCentral Nervous System (CNS) Metastases
Alpha Biopharma (Jiangsu) Co., Ltd.800 enrolled34 locationsNCT07143045
Recruiting
Phase 3
TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
HER2-positive Advanced Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.416 enrolled69 locationsNCT07047365
Recruiting
Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China
AstraZeneca200 enrolled26 locationsNCT07161388
Recruiting
Phase 2Phase 3
Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer
Locally Advanced or Metastatic Breast Cancer
Shanghai Pharmaceuticals Holding Co., Ltd254 enrolled22 locationsNCT05860465
Recruiting
Phase 3
Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients
Breast Cancer
AstraZeneca300 enrolled82 locationsNCT06635447
Recruiting
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
Breast CancerHER2-low Breast CancerHER2-positive Breast Cancer+1 more
Daiichi Sankyo800 enrolled54 locationsNCT06210776
Recruiting
Not Applicable
Robot-Assisted vs. Video-Assisted Lobectomy for NSCLC (RAVAR)
Sun Yat-sen University1,124 enrolled23 locationsNCT06524427
Recruiting
Phase 2
A Study of SKB518 in Patients With Lung Cancer
Lung Carcinoma
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.192 enrolled17 locationsNCT07019675
Recruiting
Phase 2Phase 3
A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.120 enrolled30 locationsNCT06891833
Recruiting
A Study of Treatment-Related Toxicities and Quality of Life After Local Therapy in Chinese Breast Cancer Patients
Breast NeoplasmsBreast DiseasesQuality of Life (QOL)+1 more
FangYi3,000 enrolled3 locationsNCT07010939